Literature DB >> 862646

Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.

G Campanella, S Algeri, C Cerletti, E Dolfini, A Jori, F Rinaldi.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 862646     DOI: 10.1007/bf00607673

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  26 in total

1.  A SENSITIVE METHOD FOR SPECTROPHOTOFLUOROMETRIC ASSAY OF CATECHOLAMINES.

Authors:  C C CHANG
Journal:  Int J Neuropharmacol       Date:  1964-12

2.  [Our experience in the treatment of Parkinson's disease with L-dopa plus RO 4-4602 combination].

Authors:  G Campanella; R Pennetta
Journal:  Acta Neurol (Napoli)       Date:  1974 May-Jun

3.  Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor.

Authors:  U K Rinne; V Sonninen; T Sirtola
Journal:  Z Neurol       Date:  1972

4.  Administration of a peripheral decarboxylase inhibitor with L-dopa to depressed patients.

Authors:  F K Goodwin; H K Brodie; D L Murphy; W E Bunney
Journal:  Lancet       Date:  1970-05-02       Impact factor: 79.321

5.  Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism.

Authors:  A K Granerus; T Magnusson; B E Roos; A Svanborg
Journal:  Eur J Clin Pharmacol       Date:  1974       Impact factor: 2.953

6.  The fluorometric assay of catecholamines and related compounds: improvements and extensions to the hydroxyindole technique.

Authors:  R Laverty; K M Taylor
Journal:  Anal Biochem       Date:  1968-02       Impact factor: 3.365

7.  Plasma concentration of levodopa in patients with Parkinson's disease.

Authors:  U K Rinne; V Sonninen; T Siirtola
Journal:  Eur Neurol       Date:  1973       Impact factor: 1.710

8.  The effect of L-dopa on monoamine metabolites in Parkinson's disease.

Authors:  M H van Woert; M B Bowers
Journal:  Experientia       Date:  1970

9.  [Experimental results of the combined treatment of parkinsonism using L-DOPA and a decarboxylase inhibitory agent (Ro 4-4602)].

Authors:  W Birkmayer
Journal:  Wien Klin Wochenschr       Date:  1969-09-26       Impact factor: 1.704

10.  Brain capillaries as a source of homovanillic acid in cerebrospinal fluid.

Authors:  G Bartholini; R Tissot; A Pletscher
Journal:  Brain Res       Date:  1971-03-19       Impact factor: 3.252

View more
  1 in total

1.  Effect of administration of 5-hydroxytryptophan and an inhibitor of L-aromatic amino acid decarboxylase on glucose metabolism in rat brain.

Authors:  K L Wong; G M Tyce
Journal:  Neurochem Res       Date:  1979-04       Impact factor: 3.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.